![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CA Maggi, S Giuliani, L Ballati, A Lecci, S Manzini, R Patacchini, AR Renzetti, P Rovero, L Quartara and A Giachetti
Pharmacology Department, A. Menarini Pharmaceuticals, Florence, Italy.
We have studied the effects of two newly developed tachykinin antagonists, MEN 10,207 and MEN 10,376, which are highly selective for NK-2 tachykinin receptors on tachykinin-induced contraction in the rat urinary bladder and guinea pig airways in vivo. MEN 10,207 exhibited antagonism only at doses which produced agonist effects. By contrast, MEN 10,376 was devoid of significant agonist activity at i.v. doses (1- 3 mumol/kg) which selectively antagonized the effects of an NK-2 agonist [beta-Ala8]-neurokinin A(4-10) (bladder contraction in rats, bronchoconstriction in guinea pigs) without affecting the response to an NK-1 agonist [Sar9]-substance P sulfone (hypotension, salivation and bladder contraction in rats, bronchoconstriction in guinea pigs). At these NK-2-selective blocking doses, MEN 10,376: 1) did not affect urodynamic parameters at cystometry in normal rats but reduced amplitude of micturition contractions following induction of chemical (intravesical xylene) cystitis and 2) reduced by a maximum of 50% the noncholinergic bronchoconstrictor response to vagal nerve stimulation. These findings provide the first evidence for involvement of NK-2 receptors in physiological responses in the urinary and respiratory tracts.
This article has been cited by other articles:
|
|
 |
|
  E. L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, J.-J. Bourguignon, and J.-L. Galzi A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties FASEB J, July 1, 2007; 21(9): 2124 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Womack, R. Morris, T. C. Gent, and R. Barrett-Jolley Substance P Targets Sympathetic Control Neurons in the Paraventricular Nucleus Circ. Res., June 8, 2007; 100(11): 1650 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takeuchi, K. Tanaka, H. Nakajima, M. Matsui, and Y.-T. Azuma M2 and M3 muscarinic receptors are involved in enteric nerve-mediated contraction of the mouse ileum: findings obtained with muscarinic-receptor knockout mouse Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G154 - G164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Inoue, I. Shimohira, A. Yoshida, A. Zimmer, H. Takeshima, T. Sakurada, and H. Ueda Dose-Related Opposite Modulation by Nociceptin/Orphanin FQ of Substance P Nociception in the Nociceptors and Spinal Cord J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 308 - 313. [Abstract] [Full Text]
|
|
|
|
|
|
A. R. Renzetti, R.-M. Catalioto, M. Criscuoli, P. Cucchi, C. Ferrer, A. Giolitti, M. Guelfi, L. Rotondaro, F. J. Warner, and C. A. Maggi Relevance of Aromatic Residues in Transmembrane Segments V to VII for Binding of Peptide and Nonpeptide Antagonists to the Human Tachykinin NK2 Receptor J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 487 - 495. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Inoue, M. Kobayashi, S. Kozaki, A. Zimmer, and H. Ueda Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice PNAS, September 1, 1998; 95(18): 10949 - 10953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsumoto, M. Takeda, C. Saiki, T. Takahashi, and K. Ojima Effects of Tachykinins on Rapidly Adapting Pulmonary Stretch Receptors and Total Lung Resistance in Anesthetized, Artificially Ventilated Rabbits J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1026 - 1031. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
